- Home
- TPVG vs TNGX Comparison
TPVG vs TNGX Comparison
Compare TPVG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- TNGX
- Stock Information
- Founded
- TPVG 2013
- TNGX 2014
- Country
- TPVG United States
- TNGX United States
- Employees
- TPVG N/A
- TNGX N/A
- Industry
- TPVG Other Consumer Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- TNGX Health Care
- Exchange
- TPVG Nasdaq
- TNGX Nasdaq
- Market Cap
- TPVG 286.6M
- TNGX 317.4M
- IPO Year
- TPVG N/A
- TNGX N/A
- Fundamental
- Price
- TPVG $7.14
- TNGX $1.67
- Analyst Decision
- TPVG Hold
- TNGX Strong Buy
- Analyst Count
- TPVG 5
- TNGX 7
- Target Price
- TPVG $7.31
- TNGX $12.33
- AVG Volume (30 Days)
- TPVG 364.0K
- TNGX 853.8K
- Earning Date
- TPVG 03-05-2025
- TNGX 05-07-2025
- Dividend Yield
- TPVG 16.87%
- TNGX N/A
- EPS Growth
- TPVG N/A
- TNGX N/A
- EPS
- TPVG 0.82
- TNGX N/A
- Revenue
- TPVG $108,208,000.00
- TNGX $42,069,000.00
- Revenue This Year
- TPVG N/A
- TNGX N/A
- Revenue Next Year
- TPVG $0.42
- TNGX N/A
- P/E Ratio
- TPVG $8.68
- TNGX N/A
- Revenue Growth
- TPVG N/A
- TNGX 15.17
- 52 Week Low
- TPVG $6.44
- TNGX $1.60
- 52 Week High
- TPVG $9.73
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TPVG 38.26
- TNGX 32.02
- Support Level
- TPVG $7.11
- TNGX $1.65
- Resistance Level
- TPVG $7.25
- TNGX $1.81
- Average True Range (ATR)
- TPVG 0.17
- TNGX 0.16
- MACD
- TPVG -0.03
- TNGX 0.01
- Stochastic Oscillator
- TPVG 37.34
- TNGX 8.57
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.